RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
2017-01-01 Masini, C; Vitale, Mg; Maruzzo, M; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Guida, A; Atzori, F; Mucciarini, C; Scagliarini, S; Vignani, F; Prati, G; Cosmai, L; Berselli, A; Pinto, C
CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
2017-01-01 Masini, C; Vitale, Mg; Maruzzo, M; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Guida, A; Atzori, F; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C
Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study)
2023-01-01 Catalano, Fabio; Murianni, Veronica; Rebuzzi, Sara Elena; Galuppini, Francesca; Buti, Sebastiano; Brunelli, Matteo; Maruzzo, Marco; Dei Tos, Angelo Paolo; Basso, Umberto; Banna, Giuseppe Lugi; Signori, Alessio; Sbaraglia, Marta; Damassi, Alessandra; Cremante, Malvina; Puglisi, Silvia; Gandini, Annalice; Rebuzzi, Marta; Mosca, Alessandra; Fornarini, Giuseppe; Rescigno, Pasquale
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors
2017-01-01 Bersanelli, M; Gnetti, L; Vaglio, A; Sverzellati, N; Campanini, N; Galetti, M; Incerti, M; Varotti, E; Parziale, R; Corrado, M; Bottarelli, L; Azzoni, C; Rapacchi, E; Caruso, G; Cosenza, A; Ferri, L; Silini, Em; Leonardi, F; Buti, S
Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib)
2008-01-01 Mazza, G; Archiati, E; Voltini, G; Olivetti, L; Buti, S; Passalacqua, R
Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes?
2022-01-01 Molina-Cerrillo, Javier; Ortego, Ignacio; Pinto, Alvaro; Alonso-Gordoa, Teresa; Massari, Francesco; Aurilio, Gaetano; Buti, Sebastiano; Santoni, Matteo; Grande, Enrique
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): update of a phase II study
2010-01-01 Dalla Chiesa, M; Poli, R; Tomasello, G; Lazzarelli, S; Brighenti, M; Negri, F; Curti, A; Auzzani, A; Buti, S; Liguigli, W; Passalacqua, R
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study
2010-01-01 Dalla Chiesa, M; Poli, R; Tomasello, G; Lazzarelli, S; Buti, S; Brighenti, M; Negri, F; Curti, A; Auzzani, A; Passalacqua, R
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study
2007-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Porzio, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A phase II study
2007-01-01 Chiesa, Md; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure | 1-gen-2017 | Masini, C; Vitale, Mg; Maruzzo, M; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Guida, A; Atzori, F; Mucciarini, C; Scagliarini, S; Vignani, F; Prati, G; Cosmai, L; Berselli, A; Pinto, C | |
CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure | 1-gen-2017 | Masini, C; Vitale, Mg; Maruzzo, M; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Guida, A; Atzori, F; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C | |
Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study) | 1-gen-2023 | Catalano, Fabio; Murianni, Veronica; Rebuzzi, Sara Elena; Galuppini, Francesca; Buti, Sebastiano; Brunelli, Matteo; Maruzzo, Marco; Dei Tos, Angelo Paolo; Basso, Umberto; Banna, Giuseppe Lugi; Signori, Alessio; Sbaraglia, Marta; Damassi, Alessandra; Cremante, Malvina; Puglisi, Silvia; Gandini, Annalice; Rebuzzi, Marta; Mosca, Alessandra; Fornarini, Giuseppe; Rescigno, Pasquale | |
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors | 1-gen-2017 | Bersanelli, M; Gnetti, L; Vaglio, A; Sverzellati, N; Campanini, N; Galetti, M; Incerti, M; Varotti, E; Parziale, R; Corrado, M; Bottarelli, L; Azzoni, C; Rapacchi, E; Caruso, G; Cosenza, A; Ferri, L; Silini, Em; Leonardi, F; Buti, S | |
Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib) | 1-gen-2008 | Mazza, G; Archiati, E; Voltini, G; Olivetti, L; Buti, S; Passalacqua, R | |
Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes? | 1-gen-2022 | Molina-Cerrillo, Javier; Ortego, Ignacio; Pinto, Alvaro; Alonso-Gordoa, Teresa; Massari, Francesco; Aurilio, Gaetano; Buti, Sebastiano; Santoni, Matteo; Grande, Enrique | |
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): update of a phase II study | 1-gen-2010 | Dalla Chiesa, M; Poli, R; Tomasello, G; Lazzarelli, S; Brighenti, M; Negri, F; Curti, A; Auzzani, A; Buti, S; Liguigli, W; Passalacqua, R | |
Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study | 1-gen-2010 | Dalla Chiesa, M; Poli, R; Tomasello, G; Lazzarelli, S; Buti, S; Brighenti, M; Negri, F; Curti, A; Auzzani, A; Passalacqua, R | |
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study | 1-gen-2007 | Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Porzio, R; Lazzarelli, S; Brighenti, M; Passalacqua, R | |
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A phase II study | 1-gen-2007 | Chiesa, Md; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Lazzarelli, S; Brighenti, M; Passalacqua, R |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Articolo su rivista 113
- 1 Articolo su rivista::1.5 Abstra... 113
Data di pubblicazione
- 2020 - 2023 38
- 2010 - 2019 45
- 2004 - 2009 30
Editore
- ASCO pubs 11
- Elsevier 6
- SAGE PUBLICATIONS LTD 5
- ELSEVIER 4
- BioMed Central 2
- International Institute of Antica... 1
- LIPPINCOTT WILLIAMS & WILKINS 1
- SAGE 1
Rivista
- ANNALS OF ONCOLOGY 39
- JOURNAL OF CLINICAL ONCOLOGY 39
- TUMORI 8
- I SUPPLEMENTI DI TUMORI 5
- JOURNAL OF THORACIC ONCOLOGY 4
- JOURNAL OF CLINICAL ONCOLOGY 3
- ANTICANCER RESEARCH 2
- GIORNALE ITALIANO DI NEFROLOGIA 2
- JOURNAL FOR IMMUNOTHERAPY OF CANCER 2
- ANTICANCER RESEARCH 1
Keyword
- Poster presentation at AIOM 2022 1
Lingua
- eng 95
- ita 4
- fre 1
Accesso al fulltext
- no fulltext 110
- open 3